Literature DB >> 10385491

Cholesterol lowering. Should it continue to be the last thing we do?

D Waters.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385491     DOI: 10.1161/01.cir.99.25.3215

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

Review 1.  Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis.

Authors:  J L Orford; S Kinlay; P Ganz; A P Selwyn
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

Review 2.  Endothelial dysfunction: a comprehensive appraisal.

Authors:  Ricardo J Esper; Roberto A Nordaby; Jorge O Vilariño; Antonio Paragano; José L Cacharrón; Rogelio A Machado
Journal:  Cardiovasc Diabetol       Date:  2006-02-23       Impact factor: 9.951

3.  The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

Authors:  David Waters; Gregory G Schwartz; Anders G Olsson
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.